Cellular and Molecular Biology https://cellmolbiol.org/index.php/CMB <p class="isSelectedEnd"><strong>Cellular and Molecular Biology</strong> is an international, peer-reviewed, open-access journal dedicated to publishing high-quality research that advances understanding of cellular and molecular mechanisms in biological systems.</p> <p class="isSelectedEnd">The journal publishes original research articles, reviews, mini-reviews, short communications and methods papers that provide clear mechanistic insight into cellular and molecular processes. Priority is given to manuscripts with strong scientific originality, rigorous methodology, transparent reporting, ethical compliance and conclusions supported by robust evidence.</p> <p class="isSelectedEnd">The scope of the journal includes gene regulation, epigenetics, RNA biology, cell signaling, cell cycle regulation, cell death, organelle biology, trafficking, cytoskeleton, stem cells, host–pathogen interactions, molecular microbiology, functional genomics, proteomics, quantitative imaging, CRISPR-based approaches, systems biology and computational biology supported by biological validation.</p> <p>All submissions undergo editorial screening and, when appropriate, external peer review by independent experts. Editorial decisions are based on scientific merit, relevance to the journal’s scope, methodological quality, ethical compliance and citation integrity.</p> en-US The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication. editorial.office@cellmolbiol.org (Editorial Office) editorial.office@cellmolbiol.org (Editorial Office) Fri, 18 Sep 2026 14:25:21 +0000 OJS 3.3.0.16 http://blogs.law.harvard.edu/tech/rss 60 Molecular and cellular crosstalk between atherosclerosis and cancer: Mechanistic insights and therapeutic opportunities https://cellmolbiol.org/index.php/CMB/article/view/6009 <p>Atherosclerosis and cancer are among the leading causes of morbidity and mortality worldwide and are increasingly recognized as biologically interconnected diseases rather than independent pathological conditions. Accumulating evidence indicates that these disorders share a complex molecular landscape characterized by chronic inflammation, oxidative stress, immune dysregulation, metabolic reprogramming, endothelial dysfunction, and age-related cellular alterations. This review integrates current knowledge on the molecular and cellular mechanisms underlying the bidirectional relationship between atherosclerosis and malignancy, with particular emphasis on inflammatory signaling pathways, NLRP3 inflammasome activation, macrophage polarization, clonal hematopoiesis of indeterminate potential (CHIP), cellular senescence, and gut microbiota-mediated immune modulation. We further discuss how these shared mechanisms contribute to disease initiation, progression, and therapeutic responses, highlighting the influence of cardiovascular medications on cancer biology and the cardiovascular toxicities associated with anticancer therapies. By synthesizing emerging evidence from cardiovascular biology, oncology, and immunology, this review proposes a unified molecular framework in which atherosclerosis and cancer represent interconnected manifestations of common pathogenic processes. Recognizing this molecular crosstalk provides new opportunities for the identification of shared biomarkers, improved risk stratification, and the development of mechanism-based therapeutic strategies, thereby advancing precision medicine at the interface of cardiovascular disease and cancer.</p> Alexander V. Blagov, Daria D. Borodko, Ulyana Rozhkova, Stanislav Antonov, Aleksandra Utkina, Alexander N. Orekhov Copyright (c) 2026 Alexander Blagov, Daria Borodko, Ulyana Rozhkova, Stanislav Antonov, Alexander Orekhov https://creativecommons.org/licenses/by-nc-nd/4.0 https://cellmolbiol.org/index.php/CMB/article/view/6009 Sun, 31 May 2026 00:00:00 +0000 Cognitive-enhancing effects of a herbal combination on D‑galactose‑induced memory impairment https://cellmolbiol.org/index.php/CMB/article/view/6019 Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss, for which effective pharmacological interventions remain limited. This study investigated the cognitive-enhancing effects of an optimized six‑herbal combination (HC) comprising Polygonati Rhizoma (PR), Lycium barbarum polysaccharides (LBPs), Green Tea (GT), Jujube Seeds (JS), Fructus hippophae (FH), and Mori Folium (MF). Using the Ellman method, we evaluated the acetylcholinesterase (AChE) inhibitory activities of individual herbs and HC. An L₂₅(4⁶) orthogonal design was employed to determine the optimal proportions of the six herbs, with AChE inhibition as the evaluation index. The optimal HC composition (PR 9 g, LBPs 6 g, GT 3 g, JS 3 g, FH 3 g, MF 5 g) exhibited 88.11% AChE inhibition at 2000 μg/mL, which was significantly higher than that of any individual herb (p < 0.05). Network pharmacology analysis revealed 682 common targets between HC and AD, with significant enrichment in the PI3K‑Akt signaling pathway, lipid metabolism, and chemical carcinogenesis‑receptor activation pathways, suggesting multi‑target mechanisms of action. In a D‑galactose‑induced subacute aging mouse model (3.5 g·kg⁻¹, 70 days), HC treatment (0.75, 1.5, and 3.0 g·kg⁻¹, 28 days) significantly improved spatial learning and memory in the Morris water maze. Specifically, HC at 1.5 g·kg⁻¹ significantly reduced escape latency (p < 0.01 vs. D‑galactose group), increased superoxide dismutase (SOD) and glutathione (GSH) levels (p < 0.05), and decreased malondialdehyde (MDA) and monoamine oxidase (MAO) levels (p < 0.01), while ameliorating hippocampal neuronal damage, as confirmed by hematoxylin and eosin staining. These findings demonstrate that HC exhibits potent anti‑cholinesterase activity, modulates oxidative stress, and protects against neuronal injury, positioning it as a promising multi‑target botanical candidate for further development in the prevention and management of AD. Junyan Ran, Qiwen Wei, Tao Lu, Xingjiang Liao, Xiuqing Pang, Qinfeng Zhu, Hanni Zhou, Xun He Copyright (c) 2026 Junyan Ran, Qiwen Wei, Tao Lu, Xingjiang Liao, Xiuqing Pang, Qinfeng Zhu, Hanni Zhou, Xun He https://creativecommons.org/licenses/by-nc-nd/4.0 https://cellmolbiol.org/index.php/CMB/article/view/6019 Sun, 31 May 2026 00:00:00 +0000 Autotaxin as a potential biomarker in hepatic encephalopathy: Insights from a mouse model and cirrhotic patients https://cellmolbiol.org/index.php/CMB/article/view/6010 <p>Hepatic encephalopathy (HE) is a debilitating neuropsychiatric condition associated with acute liver failure or advanced liver diseases, significantly affecting patient morbidity and mortality. Autotaxin (ATX), a lysophospholipase D that generates lysophosphatidic acid (LPA), has been proposed as a biomarker for liver fibrosis progression, but its role in HE remains poorly defined. This study aimed to explore the potential roles of ATX using in vivo TAA-induced HE models in mouse and clinical evaluations of cirrhotic patients with and without HE. ATX concentrations were quantified in plasma, liver tissue, and frontal cortex of HE mice, while ectonucleotide pyrophosphatase/phosphodiesterase 2 (Enpp2) gene expression and LPA levels were assessed in murine salivary glands. In parallel, serum and salivary ATX were measured in 7 cirrhotic patients with HE and 12 cirrhotic patients without HE. ATX concentrations were significantly elevated in the liver parenchyma and frontal cortex of TAA-induced HE mice compared to controls, whereas plasma ATX showed no significant difference. Enpp2 expression was upregulated 2.49-fold in salivary glands of HE mice, although salivary LPA concentrations did not differ between groups. Clinically, both serum and salivary ATX levels were significantly higher in cirrhotic patients with HE than in those without HE. Moreover, salivary ATX levels positively correlated with serum alkaline phosphatase (ALP) levels in the HE patient group. These findings demonstrate that ATX is elevated in key tissues and biofluids in both experimental and clinical HE, supporting its potential as a novel biomarker. Moreover, the data suggest that the ATX-LPA axis may contribute to HE pathophysiology, providing a foundation for future mechanistic studies and the exploration of targeted therapeutic strategies.</p> Ali Sepehrinezhad, Hossein Zarei, Farhad Mehravaran, Sepehr Sadr, Meysam Heydar Ahmad , Fariborz Rezaeitalab , Mahshid Mahyad, Vahid Hajali, Ali Shahbazi, Ali Beheshti Namdar , Sajad Sahab Negah Copyright (c) 2026 Ali Sepehrinezhad, Hossein Zarei, Farhad Mehravaran, Sepehr Sadr, Meysam Heydar Ahmad , Fariborz Rezaeitalab , Mahshid Mahyad, Vahid Hajali, Ali Shahbazi, Ali Beheshti Namdar , Sajad Sahab Negah https://creativecommons.org/licenses/by-nc-nd/4.0 https://cellmolbiol.org/index.php/CMB/article/view/6010 Sun, 31 May 2026 00:00:00 +0000 Chelidonium majus L. alkaloid extract encapsulated in human serum albumin nanoparticles induces mitochondria-mediated apoptosis in HeLa cell line https://cellmolbiol.org/index.php/CMB/article/view/6018 Interest in herbal medicines as complementary therapies has increased because of concerns regarding the adverse effects of conventional chemotherapeutic agents. Chelidonium majus L. (C. majus) exhibits antiproliferative activity against several cancer cell lines; however, its therapeutic efficacy may be limited by poor bioavailability. This study evaluated the apoptotic activity of C. majus alkaloid extract encapsulated in human serum albumin nanoparticles (C. majus/HSA-NPs) in HeLa cervical cancer cells. Cytotoxicity of C. majus alkaloid extract (C. majus/AE), C. majus/HSA-NPs, and HSA-NPs was determined using the MTT assay in HeLa and human fibroblast cells, apoptosis was quantified by Annexin V/PI flow cytometry, and the mRNA expression of Bax, Bcl-2, caspase-9 and caspase-3 was analyzed by real-time RT-PCR. After 48 h, the IC₅₀ values in HeLa cells were 70.79 μg/mL for C. majus/AE, 52.37 μg/mL for C. majus/HSA-NPs, and >2000 μg/mL for HSA-NPs, whereas fibroblast cells exhibited substantially higher IC₅₀ values (835 μg/mL for C. majus/AE and >1600 μg/mL for both C. majus/HSA-NPs and HSA-NPs), indicating selective cytotoxicity toward cancer cells. C. majus/HSA-NPs induced significantly greater apoptosis than the free alkaloid extract and markedly enhanced the expression of the pro-apoptotic genes Bax, caspase-9, and caspase-3, while suppressing Bcl-2, resulting in a significantly higher Bax/Bcl-2 ratio, consistent with activation of the mitochondrial apoptotic pathway. Overall, nanoencapsulation with human serum albumin enhanced the anticancer efficacy of C. majus alkaloids while maintaining low toxicity toward normal fibroblasts, suggesting that C. majus/HSA-NPs represent a promising candidate for targeted cervical cancer therapy, although further in vivo and mechanistic studies are required to confirm their therapeutic potential. Mahdieh Imani, Masoud Parsania, Fatemeh Rouhollah, Mohammad Hassan Pouriayevali Copyright (c) 2026 Mahdieh Imani, Masoud Parsania, Fatemeh Rouhollah, Mohammad Hassan Pouriayevali https://creativecommons.org/licenses/by-nc-nd/4.0 https://cellmolbiol.org/index.php/CMB/article/view/6018 Sun, 31 May 2026 00:00:00 +0000 Congruency of exosome-mediated blood–brain barrier dysfunction by activation of Na/K-ATPase in obstructive sleep apnea and Alzheimer's disease https://cellmolbiol.org/index.php/CMB/article/view/6012 <p>Obstructive sleep apnea (OSA) and Alzheimer's disease (AD) are highly prevalent chronic disorders that share several pathological features, including oxidative stress, inflammation, vascular dysfunction, and cognitive impairment. Although epidemiological studies have demonstrated a strong association between OSA and an increased risk of AD, the mechanisms linking these disorders remain poorly understood. We hypothesized that circulating plasma exosomes from patients with OSA or AD disrupt blood–brain barrier (BBB) integrity through activation of Na⁺/K⁺-ATPase signaling. Plasma exosomes were isolated from adult male patients with OSA or AD (n = 10/group) and applied to naïve human brain microvascular endothelial cells (hCMEC/D3). BBB integrity was continuously monitored using electric cell-substrate impedance sensing (ECIS) in the presence or absence of the Na⁺/K⁺-ATPase signaling inhibitor pNaKtide (0–2.0 µM). Exosomes derived from both OSA and AD patients significantly impaired endothelial barrier function, indicating that circulating extracellular vesicles carry bioactive cargo capable of disrupting BBB integrity. Pharmacological inhibition of Na⁺/K⁺-ATPase signaling with pNaKtide significantly restored barrier function at concentrations of 1.0 and 2.0 µM, although the degree of protection differed between the OSA- and AD-derived exosomes, suggesting disease-specific mechanisms of endothelial injury. These findings identify Na⁺/K⁺-ATPase signaling as a key mediator of exosome-induced BBB dysfunction and provide mechanistic evidence linking circulating extracellular vesicles to neurovascular injury in both OSA and AD. Collectively, our results suggest that plasma-derived exosomes contribute to BBB disruption and highlight Na⁺/K⁺-ATPase signaling as a promising therapeutic target for preventing or attenuating neurovascular dysfunction associated with OSA and AD.</p> Abdelnaby Khalyfa, Jose M. Marin, David Sanz-Rubio, Sneha S. Pillai , Xiaoman Zhang, David Gozal, Komal Sodhi Copyright (c) 2026 Abdelnaby Khalyfa, Jose M. Marin, David Sanz-Rubio, Sneha S. Pillai , Xiaoman Zhang, David Gozal, Komal Sodhi https://creativecommons.org/licenses/by-nc-nd/4.0 https://cellmolbiol.org/index.php/CMB/article/view/6012 Sun, 31 May 2026 00:00:00 +0000 Molecular epidemiology of antimicrobial-resistant Klebsiella pneumoniae in intensive care unit patients, southwestern Saudi Arabia https://cellmolbiol.org/index.php/CMB/article/view/6011 <p>Antimicrobial resistance (AMR) in Gram-negative pathogens poses a critical threat in intensive care units (ICUs). This retrospective observational study aimed to determine the prevalence and phenotypic resistance profiles of extended-spectrum β‑lactamase (ESBL)-producing and carbapenem‑resistant Klebsiella pneumoniae among ICU patients at a tertiary hospital in southwestern Saudi Arabia (2020–2021). Clinical specimens (n=179) from patients with hospital‑acquired infections were processed using standard culture, Vitek 2 identification, and phenotypic confirmatory tests (combination disc test for ESBLs and modified carbapenem inactivation method for carbapenemase). Of 543 total samples, 49 (9.0%) were identified as K. pneumoniae. ESBL production was detected in 15/49 (30.6%) and carbapenemase production in 6/49 (12.2%) of isolates. The highest resistance rates were observed against piperacillin‑tazobactam (55.1%), cefotaxime (55.1%), imipenem (53.0%), and meropenem (53.0%), while tigecycline (100% susceptibility) and amikacin (93.9% susceptibility) remained the most effective agents. Notably, susceptibility to trimethoprim‑sulfamethoxazole was 83.7% (corrected figure). Children under 10 years and adults aged 21–40 years showed the highest infection rates. The alarmingly high prevalence of ESBL and carbapenemase phenotypes, coupled with significant multidrug resistance, underscores the urgent need for routine molecular surveillance and targeted antibiotic stewardship in this region. Rapid phenotypic screening combined with genotypic confirmation is essential to guide empirical therapy and curb the spread of these high‑risk clones in critically ill populations.</p> Abdullah I. Abdullah I Copyright (c) 2026 Abdullah I Aedh Abdullah I Aedh https://creativecommons.org/licenses/by-nc-nd/4.0 https://cellmolbiol.org/index.php/CMB/article/view/6011 Sun, 31 May 2026 00:00:00 +0000 Selegiline induces neuroprotection via PGC-1α/Nrf2 gene upregulation in H2O2 -treated hippocampal-derived neural stem/progenitor cells https://cellmolbiol.org/index.php/CMB/article/view/6007 <p>Oxidative stress mediated by reactive oxygen species (ROS) is a major contributor to the pathogenesis of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s, multiple sclerosis, and amyotrophic lateral sclerosis. Selegiline, a monoamine oxidase B inhibitor, has been reported to exert neuroprotective effects, although its precise cytoprotective mechanisms remain unclear. In this study, we investigated the effects of selegiline on apoptosis, necrosis, and cell survival in hydrogen peroxide (H₂O₂)-treated hippocampal-derived neural stem/progenitor cells (HD-NSPCs) in vitro. Passage 3 HD-NSPCs were treated with varying concentrations of selegiline (10⁻³ to 10⁻⁹ M) prior to exposure to 125 μM H₂O₂. Cell viability was assessed using the MTT assay, while apoptosis and necrosis were evaluated using TUNEL and acridine orange/ethidium bromide staining, respectively. Real-time RT-PCR was performed to quantify mRNA levels of PGC-1α, Nrf2, and Bcl-2. Treatment with 10⁻⁷ M selegiline significantly enhanced HD-NSC viability, reduced apoptotic and necrotic cell fractions, and upregulated PGC-1α, Nrf2, and Bcl-2 expression compared to untreated cells (P &lt; 0.05). These findings suggest that selegiline mitigates oxidative stress–induced cytotoxicity by activating Nrf2/PGC-1α signaling and promoting anti-apoptotic gene expression, thereby preserving mitochondrial function and enhancing cell survival. Overall, selegiline may represent a promising therapeutic agent for protecting neural progenitor cells and alleviating neuronal damage in neurodegenerative disorders.</p> Alireza Abdanipour, Ali Nikfar, Hadi Feizi Copyright (c) 2026 Alireza Abdanipour, Ali Nikfar, Hadi Feizi https://creativecommons.org/licenses/by-nc-nd/4.0 https://cellmolbiol.org/index.php/CMB/article/view/6007 Sun, 31 May 2026 00:00:00 +0000 GALNS gene variants and clinical severity in pediatric mucopolysaccharidosis type IV: A retrospective cohort study from Duhok, Iraq https://cellmolbiol.org/index.php/CMB/article/view/6008 <p>Mucopolysaccharidosis type IV (MPS IV; Morquio syndrome) is a rare lysosomal storage disorder caused by pathogenic variants in the GALNS gene, resulting in deficiency of N-acetylgalactosamine-6-sulfatase and progressive accumulation of glycosaminoglycans. The disease exhibits substantial clinical heterogeneity, and the relationship between specific GALNS variants and disease severity remains incompletely understood. This retrospective cross-sectional observational study evaluated the association between GALNS variants and clinical severity in 10 children with genetically confirmed MPS IV treated at a tertiary pediatric center in Duhok, Iraq, with data collected up to September 2025. Clinical, radiological, echocardiographic, and genetic data were retrospectively extracted from medical records. A study-derived, non-validated Clinical Severity Index (CSI; range, 0–6) was constructed from six clinically relevant skeletal, neurological, and functional manifestations, with higher scores indicating greater recorded disease burden. Three GALNS variants were identified: c.860C&gt;T (50%), c.421T&gt;A (30%), and c.1196delA (20%). The overall mean CSI was 2.9 ± 2.0. Patients with the frameshift variant c.1196delA had the highest mean CSI (4.0 ± 1.4), followed by c.860C&gt;T (2.8 ± 2.6) and c.421T&gt;A (2.3 ± 0.6); however, the difference among mutation groups was not statistically significant (Kruskal–Wallis p = 0.564). Overall, 20% of patients had mild, 50% had moderate, and 30% had severe disease according to the study-derived CSI. Multisystem involvement was common, including skeletal abnormalities in 70%, abnormal echocardiographic findings in 70%, cervical spinal cord compression in 30%, and carpal tunnel syndrome and/or communicating hydrocephalus in 40% of patients. The findings demonstrate substantial clinical variability among children with MPS IV and suggest a possible trend toward greater disease burden among patients with the frameshift variant c.1196delA, although this association was not statistically significant. Given the small sample size and the non-validated nature of the CSI, these findings should be considered exploratory and require confirmation in larger, multicenter cohorts using standardized clinical and biochemical measures.</p> bashar I. Mohammed Copyright (c) 2026 bashar Ibrahim https://creativecommons.org/licenses/by-nc-nd/4.0 https://cellmolbiol.org/index.php/CMB/article/view/6008 Sun, 31 May 2026 00:00:00 +0000